AI Drug Discovery Specialist Interview Questions

A strong answer explains bit-vector or count-based encodings (e.g., Morgan/ECFP), their fixed-length representation of substructures, and why they enable classical ML on molecules.

Covers the funnel from initial screening hits → optimized leads with acceptable properties → candidates nominated for preclinical development.

Covers string-based molecular representation, canonical vs. non-canonical SMILES, and issues like invalid sequences and lack of 3D information.

Explains that scaffold splitting tests generalization to novel chemical scaffolds, avoiding data leakage from structurally similar molecules in the training set.

Absorption, Distribution, Metabolism, Excretion, Toxicity - mentions tools like SwissADME, pkCSM, or custom ML models for each.

Discusses atoms as nodes, bonds as edges, message-passing mechanisms, and the ability to learn task-specific representations without fixed feature engineering.

Covers target preparation, binding site identification, compound library selection, docking protocol setup, rescoring with ML, and hit triage criteria.

Covers SA score (Ertl & Schuffenhauer), retrosynthetic analysis, and how generative models are constrained or filtered to produce synthetically feasible molecules.

Ligand-based uses known active molecules (pharmacophore, similarity); structure-based uses 3D protein structure (docking, FEP). Use each depending on target structural availability.

Covers techniques like SMOTE, undersampling, focal loss, class weights, evaluation metrics (AUC-PR, MCC), and active learning to prioritize informative experiments.

Explains the encoder-decoder architecture that operates on molecular substructures (tree decomposition of molecular graphs) rather than raw SMILES characters.

Docking scores estimate binding affinity but have known inaccuracies; ML rescoring models trained on binding data can improve hit rates and reduce false positives.

Discusses DVC for data versioning, MLflow or W&B for model tracking, Git for code, and the importance of reproducible random seeds and environment specification.

Covers MW, LogP, HBD, HBA thresholds; discusses that many modern drugs violate these rules (e.g., PROTACs, macrocycles) and how AI can optimize beyond simple rules.

Explains masked language modeling on evolutionary sequences, the information captured in attention patterns, and how embeddings can be fine-tuned for downstream tasks.

Diffusion models offer stable training and high-quality samples but can be slow; RL optimizes reward functions directly but suffers from mode collapse and reward hacking.

Covers uncertainty-based acquisition functions, batch selection strategies, integration with experimental feedback, and the balance between exploitation and exploration.

Discusses grounding LLMs with structured chemical databases, RAG over validated literature, confidence calibration, and the need for domain-specific fine-tuning.

Covers Pareto optimization, scalarization strategies, constrained Bayesian optimization, and how to present trade-off landscapes to medicinal chemists.

Discusses novelty metrics (Tanimoto distance from training set), diversity metrics (internal diversity, scaffold diversity), uniqueness, and validity rates.

Covers thermodynamic cycle calculations, relative binding free energy accuracy (~1 kcal/mol), GPU cost, and when FEP adds value over docking or ML rescoring.

Covers ETL design, knowledge graph construction, entity resolution across databases, and the use of graph databases or vector stores for cross-modal retrieval.

Discusses attention visualization, atom-level attribution (GNNExplainer, SHAP), pharmacophore highlighting, and generating natural-language rationales via LLMs.

Covers zero-shot and few-shot transfer learning, reduced need for task-specific data, emergent capabilities, and risks of centralizing capabilities in a few models.

Covers chemical proteomics, reverse docking, gene expression signature matching (L1000/CMap), and ML models for target prediction based on chemical structure.

Great answers discuss adding solubility as a hard constraint or reward term, retraining with solubility-augmented data, and applying Pareto filters post-generation.

Covers transfer learning from related targets, few-shot learning, data augmentation via molecular similarity, leveraging pretrained models, and uncertainty quantification.

Discusses rescoring with ML, consensus docking, pharmacophore post-filtering, ADMET filtering, relaxed complex generation, and re-examining binding site definition.

Covers connectivity map analysis, target-pathway mapping, off-target prediction, pediatric PK modeling, and regulatory considerations for orphan drug designation.

Discusses incorporating synthetic accessibility scores, retrosynthetic analysis tools (ASKCOS, IBM RXN), and training with synthesis-aware constraints.

Covers multi-task learning, heterogeneous graph networks (drug-drug-enzyme graphs), knowledge graph embeddings, and training on FDA FAERS and DrugBank data.

Covers model cards, feature importance analysis, decision rationale generation, data provenance documentation, and comparison against established baselines.

Discusses inference latency, scalability, interpretability, maintenance complexity, team familiarity, and performance on edge cases specific to your chemical space.

Covers chemical space visualization (t-SNE, UMAP), diversity analysis, stratified sampling, reweighting, and active learning to fill data gaps.

Covers data harmonization (assay normalization, endpoint mapping), multi-task learning, transfer learning, domain adaptation, and validation on held-out proprietary data.

Covers RDKit descriptor calculator, Pandas DataFrame pipeline, PyTorch Dataset/DataLoader, model architecture, training loop, and evaluation.

Covers document loading, chunking strategies for scientific papers, embedding with domain-specific models, vector store selection (Pinecone, FAISS), and prompt engineering for chemical queries.

Covers tokenization of SMILES, dataset preparation, Trainer API configuration, hyperparameter tuning, and evaluation on scaffold-split test sets.

Covers SageMaker endpoint creation, container configuration, model serialization, auto-scaling policies, monitoring with CloudWatch, and A/B testing setup.

Covers Nextflow DSL2 processes, channel operations for compound batching, SLURM/AWS Batch executor configuration, retry strategies, and results aggregation.

Covers wandb.init configuration, logging metrics and artifacts, sweep configurations for hyperparameter search, and dashboard creation for cross-team visibility.

Covers extracting per-residue or pooled embeddings from ESM-2, combining with ligand features, building a cross-attention or concatenation-based fusion model, and training strategy.

Covers acquisition function design (EHVI, ParEGO), surrogate model training, candidate proposal, Pareto front tracking, and experimental feedback integration.

Covers DVC for data versioning with S3/GCS remotes, Git for code, MLflow model registry for model artifacts, and linking dataset versions to model versions via metadata tags.

Covers Dockerfile with conda/pip for RDKit, multi-stage builds, FastAPI with Pydantic request/response models, health checks, and container registry deployment.

Strong answers describe adapting language, using visualizations, tying results to business/clinical outcomes, and confirming understanding through iterative feedback.

Covers respectful investigation of both perspectives, designing targeted experiments to resolve uncertainty, and being open to model limitations.

Describes concrete habits (arXiv monitoring, conference attendance, journal clubs) and a specific instance where a new paper or tool changed their approach.

Covers pragmatic decision-making, stakeholder communication, documentation of trade-offs, and iterative improvement plans.

Covers structured learning plans, pairing on projects, patience with iterative explanations, celebrating incremental progress, and connecting ML concepts to biological intuition.